0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Osteopontin as a Biomarker for Ovarian Cancer

Jeffrey D. Seidman, MD
JAMA. 2002;287(24):3208-3210. doi:10.1001/jama.287.24.3206.
Text Size: A A A
Published online

Extract

To the Editor: In their study, Dr Kim and colleagues1 frequently combined ovarian carcinomas with ovarian "borderline tumors." This grouping is not valid. Although pathologists disagree on terminology for "borderline tumors," they agree on the behavior of this heterogeneous group. The vast majority (about 90%) of serous borderline tumors (the most common type) are benign with virtually 100% survival.2 The aggressive serous borderline tumors have a micropapillary pattern and/or invasive peritoneal implants, and patients with these tumors have a 7-year survival of 60% to 70%.2 Mucinous borderline tumors comprise nearly all the remaining borderline tumors, and aggressive mucinous borderline tumors, previously thought to be ovarian, are now acknowledged to be of gastrointestinal origin.2 The remaining ovarian mucinous borderline tumors are virtually always confined to the ovaries and patients have 100% survival.2 Thus, the grouping of borderline tumors with carcinomas intermixes benign with malignant tumors and renders the results uninterpretable.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 2

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();